ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that a scientific track has been dedicated to Tumor Treating Fields at the 40th International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS), July 17 through July 21 in Honolulu, Hawaii. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. The IEEE Engineering in Medicine and Biology Society’s 40th International Conference is the first conference in which Tumor Treating Fields will be featured in a dedicated scientific track, increasing awareness of Novocure’s proprietary therapy among the scientific community.
The track, “Computational Human Models V: Tumor Treating Fields,” will feature six oral presentations and will be chaired by Dr. Ze’ev Bomzon, Novocure’s Director of Science, and Dr. Eric T. Wong, Associate Professor of Neurology at Harvard Medical School and Co-Director of the Brain Tumor Center at Beth Israel Deaconess Medical Center in Boston. An additional track will feature a seventh oral presentation on Tumor Treating Fields by Novocure Senior Physicist Dr. Cornelia Wenger, who will chair a track titled “Computational Human Models VI: Emerging modeling and measurement techniques.” Tumor Treating Fields is among a broad array of scientific tracks covering diverse topics of cutting-edge research, technology transfer and entrepreneurship, and biomedical engineering education. Novocure also will present in a workshop on energy-based cancer therapeutics.
“We are proud that EMBS has recognized Tumor Treating Fields as an important area of concentration for the attendees of its conference,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. “We believe the focus of Tumor Treating Fields at this meeting will help generate awareness and understanding of our therapy among the scientific community. We look forward to participating in this scientific exchange and educating the community on the science of our therapy.”
(Abstract ThCT20.5) Connecting TTFields Distribution to Patient Outcome: A Study Utilizing Simulations of TTFields Distributions in Over 100 Patients (I). Z. Bomzon. 2:30 to 2:45 p.m. HST Thursday, July 19.
(Abstract ThCT20.4) Insights from Computer Modeling: Analysis of Physical Characteristics of Glioblastoma in Patients Treated with TTFields (I). E. Wong. 2:15 to 2:30 p.m. HST Thursday, July 19.
(Abstract ThCT20.3) Estimating the Intensity and Anisotropy of Tumor Treating Fields Using Matrix Decomposition towards a More Comprehensive Estimation of Anti-Tumor Efficacy (I). A. Korshøj. 2 to 2:15 p.m. HST Thursday, July 19
(Abstract ThCT20.1) Advanced Multiparametric Imaging for Response Assessment to TTFields in Patients with Glioblastoma (I) S. Mohan. 1:30 to 1:45 p.m. HST Thursday, July 19.
(Abstract ThCT20.6) Simulating the Effect of 200 Khz AC Electric Fields on Tumor Cell Structures to Uncover the Mechanism of a Cancer Therapy (I). K. Carlson. 2:45 to 3 p.m. HST Thursday, July 19.
(Abstract ThCT20.2) Electroconductive Properties of Microtubules, Actin and Kinesin (I) J. Tuszyński. 1:45 to 2 p.m. HST Thursday July, 19.
(Abstract FrAT20.4) Water-Content Electrical Property Tomography (wEPT) for Mapping Brain Tissues' Conductivity in the 100-1000 Khz Range: Results of an Animal In-Vivo Study (I). C. Wenger. 8:45 to 9 a.m. HST Friday, July 20.
IEEE Engineering in Medicine and Biology Society is the world’s largest international society of biomedical engineers. The organization’s 12,000 members reside in some 97 countries around the world. EMBS provides its members with access to the people, practices, information, ideas and opinions that are shaping one of the fastest growing fields in science.
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2018, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.